Pharmacology, Toxicology and Pharmaceutical Science
Ribavirin
68%
Placebo
38%
Adverse Event
38%
Hepatitis C
37%
Sofosbuvir
37%
Infection
37%
Hepatitis C Virus
36%
Nonalcoholic Fatty Liver
33%
Liver Cirrhosis
33%
Chronic Hepatitis C
30%
Antivirus Agent
29%
Peginterferon
25%
Hepatitis C Virus Genotype 1
25%
Fibrosis
24%
Pharmacokinetics
20%
Virus RNA
19%
Interferon
15%
Daclatasvir
12%
Clinical Trial
12%
Boceprevir
11%
RNA
10%
Antiviral Activity
9%
Blindness
9%
Monotherapy
9%
Ledipasvir Plus Sofosbuvir
8%
Drug
8%
Simeprevir
8%
Ledipasvir
8%
Nonstructural Protein 5A Inhibitor
8%
Velpatasvir
7%
Proteinase Inhibitor
7%
Telaprevir
7%
Deterioration
7%
Peginterferon Alpha2a
7%
Tolerability
7%
Ritonavir
6%
Decompensated Liver Cirrhosis
5%
Alanine Aminotransferase
5%
Vaniprevir
5%
Headache
5%
Fatigue
5%
Medicine and Dentistry
Patient
100%
Therapeutic Procedure
48%
Inpatient
38%
Nonalcoholic Fatty Liver
36%
Fibrosis
26%
Ribavirin
21%
Liver Cirrhosis
18%
Combination Therapy
17%
Genotype
14%
Placebo
13%
Hepatitis C Virus
12%
Chronic Hepatitis C
12%
Hepatitis C
12%
Infection
12%
Antivirus Agent
11%
Peginterferon
11%
Adverse Event
11%
Sofosbuvir
10%
Liver
9%
Clinical Trial
8%
Analysis
7%
Hepatitis C Virus Genotype 1
7%
Development
5%
Interferon
5%
Liver Fibrosis
5%
Arm
5%
Steatohepatitis
5%
Nursing and Health Professions
Patient
40%
Ribavirin
29%
Sustained Virologic Response
18%
Inpatient
15%
Peginterferon
12%
Hepatitis C
12%
Combination Therapy
11%
Liver Cirrhosis
11%
Chronic Hepatitis C
9%
Infection
8%
Sofosbuvir
7%
Patient-Reported Outcome
6%
Telaprevir
6%
Adverse Event
6%
Nonalcoholic Fatty Liver
6%
Analysis
6%
Fibrosis
6%
Confidence Interval
5%
Procedures
5%
